Core Viewpoint - Nanmo Biological (688265.SH) has received its first research funding of 1.1393 million yuan from a national major project, with a portion allocated to other research units [1] Group 1: Financial Impact - The research funding includes 0.3571 million yuan directly received by the company, which represents 5.50% of the company's audited net profit for the most recent fiscal year [1] - The total expected research funding for the company is 4.1524 million yuan, which will also be government subsidies related to revenue, accounting for 63.93% of the company's audited net profit for the last fiscal year [1] Group 2: Funding Allocation - Out of the total funding, 0.7822 million yuan is to be allocated to other participating research units [1] - The remaining funds will be disbursed in batches based on actual progress and final acceptance [1]

Group 1 - Company Nanmo Biology announced that its wholly-owned subsidiary, Shanghai Dish Biotech Co., Ltd. (referred to as "Dish Biotech"), received the first tranche of research funding from a national major project amounting to 1.1393 million yuan, of which 782,200 yuan will be allocated to other participating research units [1] - Dish Biotech received 357,100 yuan in research funding, which is a government subsidy related to revenue, accounting for 5.50% of the company's audited net profit for the most recent fiscal year [1] - According to the National Science and Technology Major Project task book, Dish Biotech is expected to receive a total of 4.1524 million yuan in research funding, all of which are government subsidies related to revenue, accounting for 63.93% of the company's audited net profit for the most recent fiscal year [1]

证券代码：688265 证券简称：南模生物 公告编号：2026-008 上海南方模式生物科技股份有限公司 关于子公司获得政府补助的公告 特此公告。 上海南方模式生物科技股份有限公司董事会 2026 年 2 月 28 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）的全资子公司上 海砥石生物科技有限公司（以下简称"砥石生物"）于近日收到了国家重大专项 的首笔科研经费 113.93 万元，其中 78.22 万元需划拨至其他参研单位。砥石生物 本次获得的科研经费为 35.71 万元，属于与收益相关的政府补助，占公司最近一 个会计年度经审计净利润的比例为 5.50%。 根据《国家科技重大专项课题任务书》，砥石生物预计累计可获得科研经费 415.24 万元，均为与收益相关的政府补助，占公司最近一个会计年度经审计净利 润的比例为 63.93%。剩余款项将根据实际进展及最终验收情况分批拨付。 二、补助的类型及其对公司的影响 公司根据《企业会计准则第 16 号 ...

证券代码：688265 证券简称：南模生物 公告编号：2026-009 上海南方模式生物科技股份有限公司 2026年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 27 日 （二） 股东会召开的地点：上海市浦东新区琥珀路 63 弄 1 号 M10 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 1、 关于补选公司第四届董事会非独立董事的议案 | 议案 | 议案名称 | 得票数 | 得票数占出席会议有 | 是否当选 | | --- | --- | --- | --- | --- | | 序号 | | | 效表决权的比例（%） | | | 1.01 | 选举张书林为第四届 | 53,953,760 | 99.8832 | 是 | | | 董事会非独立董事 | | | | | 1、出席会议的股东和代理人人数 | 34 | | -- ...

中国北京市建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于上海南方模式生物科技股份有限公司 2026 年第二次临时股东会的法律意见书 致：上海南方模式生物科技股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股 东会规则》（以下简称"《股东会规则》"）《律师事务所证券法律业务执业 规则（试行）》等法律、法规及规范性文件和《上海南方模式生物科技股份有 限公司章程》（以下简称"《公司章程》"）的相关规定，北京市通商律师事 务所（以下简称"本所"）接受上海南方模式生物科技股份有限公司（以下简 称"公司"）委托，指派律师出席了公司于 2026 年 2 月 27 ...

Financial Performance - The company achieved total operating revenue of approximately 42,125.86 million RMB, representing a year-on-year increase of 10.50%[2] - The net profit attributable to shareholders of the parent company was approximately 3,243.13 million RMB, a significant year-on-year increase of 399.29%[2] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was approximately 940.81 million RMB, marking a turnaround from a loss in the previous year[2] - Basic earnings per share increased to 0.43 RMB, up 436.11% compared to the previous year[2] - The weighted average return on net assets rose to 1.91%, an increase of 1.53 percentage points year-on-year[2] Assets and Equity - Total assets at the end of the reporting period were 198,204.66 million RMB, reflecting a 2.73% increase from the beginning of the period[2] - The equity attributable to shareholders of the parent company was 171,005.16 million RMB, up 1.61% from the beginning of the period[2] Factors Influencing Performance - The company attributed its performance improvement to a recovery in the domestic biopharmaceutical industry and effective cost control measures[7] - Government subsidies and other non-recurring income contributed to the increase in net profit[8] Financial Data Disclaimer - The company emphasizes that the financial data is preliminary and subject to audit, urging investors to be aware of investment risks[9]

Group 1 - The core viewpoint of the article is that Nanmo Biological announced its financial projections for 2025, indicating significant growth in both revenue and net profit [1] Group 2 - The total operating revenue for 2025 is projected to be 421.2586 million yuan, representing a year-on-year increase of 10.50% [1] - The net profit attributable to the parent company is expected to reach 32.4313 million yuan, showing a remarkable year-on-year growth of 399.29% [1]

Core Viewpoint - The medical services sector experienced a decline of 1.13% on February 26, with Nanmo Biological leading the drop [1] Market Performance - The Shanghai Composite Index closed at 4146.63, down 0.01% - The Shenzhen Component Index closed at 14503.79, up 0.19% [1] Capital Flow - The medical services sector saw a net outflow of 929 million yuan from main funds - Retail investors contributed a net inflow of 612 million yuan, while speculative funds saw a net inflow of 317 million yuan [1]

2026 年第二次临时股东会会议资料 公司代码：688265 公司简称：南模生物 上海南方模式生物科技股份有限公司 2026 年第二次临时股东会会议资料 二〇二六年二月 1 2026 年第二次临时股东会会议资料 目 录 | 2026 | 年第二次临时股东会会议须知 3 | | --- | --- | | 2026 | 年第二次临时股东会投票议程 5 | | 议案一 | 关于补选公司第四届董事会非独立董事的议案 7 | 上海南方模式生物科技股份有限公司 2026 年第二次临时股东会会议须知 2 2026 年第二次临时股东会会议资料 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据中国证监会《上市公司股东会规则》以及《上海南方模式生 物科技股份有限公司章程》（以下简称"《公司章程》"）《上海南方模式生物 科技股份有限公司股东会议事规则》（以下简称"《股东会议事规则》"）的相 关规定，特制定 2026 年第二次临时股东会会议须知： 一、本公司根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》《公司章程》及《股东会议事规则》的规定，认真做好召开 股东会的 ...

Core Viewpoint - The refinancing market is undergoing targeted adjustments with the introduction of new policies aimed at supporting high-quality and innovative companies, simplifying processes, and preventing risks [1] Group 1: Refinancing Policy Adjustments - The new refinancing policy reduces the interval for companies that are unprofitable and meet specific criteria from 18 months to 6 months, allowing them to initiate new rounds of refinancing more quickly [2] - Companies in the high-tech sector express that the new policy will facilitate continuous funding for product development and commercialization, thus supporting their growth [2] Group 2: Support for Underperforming Companies - The new policy allows companies that have experienced stock price declines to engage in refinancing through methods such as private placements and convertible bonds, provided the funds are directed towards their main business [4] - As of February 10, there are 553 companies listed on the exchanges that are currently underperforming, indicating a significant potential for these companies to leverage the new refinancing options [4] Group 3: Expansion of Fund Utilization - The new policy encourages high-quality companies to allocate funds towards new industries, business models, and technologies that align with their main operations, thus promoting a second growth curve [6] - This shift from strict limitations on fund allocation to a more flexible approach is expected to enhance capital flow into high-tech industries and improve resource allocation efficiency [6]